Business
Decibel Announces TSX Venture Exchange Acceptance for AgMedica Acquisition and Debenture Conversion
Decibel Announces TSX Venture Exchange Acceptance for AgMedica Acquisition and Debenture Conversi...
About this update from Decibel Cannabis Company Inc
[{"type":"text","content":"\n\n\n\n Decibel Announces TSX Venture Exchange Acceptance for AgMedica Acquisition and Debenture Conversion\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN\n \n THE UNITED STATES\n \n . ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./\n \n\n\n\n\n\n CALGARY, AB\n \n\n ,\n \n\n Dec. 3, 2024\n \n\n /CNW/ - Decibel Cannabis Company Inc. (the \"\n \n Company\n \n \" or \"\n \n Decibel\n \n \") (TSXV: DB) (OTCQB: DBCCF), a market leader in premium cannabis and extract manufactured products, is pleased to announce that it has received final acceptance from the TSX Venture Exchange (the \"\n \n TSXV\n \n \") for its previously announced acquisition of AgMedica Bioscience Inc. (\"\n \n AgMedica\n \n \") on\n \n October 28, 2024\n \n pursuant to an assignment agreement entered into with Callisto Capital Corp. (\"\n \n Callisto\n \n \") in exchange for a\n \n $6.3 million\n \n unsecured convertible debenture (the \"\n \n Convertible Debenture\n \n \").  As a result of receiving the acceptance, Decibel has completed the conversion of the Convertible Debenture, pursuant to which it has issued 114,545,455 common shares (\"\n \n Common Shares\n \n \") to Callisto.\n \n\n\n\n\n\n\n\n\n The conversion of the Convertible Debenture was conditional upon receipt of final TSXV acceptance for the acquisition of AgMedica pursuant to Exchange Policy 5.3, which would have required disinterested shareholder approval of Callisto as a \"Control Person\" (as such term is defined in the rules and policies of the TSXV), if applicable.  As a result of the Company having completed its previously announced private placement, Callisto will not be a Control Person of the Company following conversion of the Convertible Debenture and therefore approval of the disinterested shareholders of the Company is not required for the conversion.\n \n\n Please see the Company's news release dated\n \n October 28, 2024\n \n...